Shares of Kala Pharmaceuticals KALA fell 0.5% in pre-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share increased 9.26% over the past year to ($0.49), which beat the estimate of ($0.68).
Revenue of $3,266,000 higher by 204.95% from the same period last year, which missed the estimate of $4,180,000.
Guidance
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Details Of The Call
Date: May 05, 2021
Time: 08:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/yu62x3fd
Recent Stock Performance
Company's 52-week high was at $14.68
52-week low: $6.00
Price action over last quarter: down 13.36%
Company Description
Kala Pharmaceuticals Inc is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye. The company's two marketed products are EYSUVIS and INVELTYS.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
